<DOC>
	<DOCNO>NCT00609921</DOCNO>
	<brief_summary>This Phase 1 , open label , dose escalation study ARQ 197 patient advanced/recurrent solid tumor . The purpose study determine safety , tolerability recommend Phase 2 dose ( RP2D ) ARQ 197 .</brief_summary>
	<brief_title>A Phase 1 Study ARQ 197 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients respond refractory available therapy standard effective systemic therapy exists . Karnofsky performance status ( KPS ) â‰¥ 70 % , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients adequate organ function Anticancer chemotherapy , hormonal therapy , radiotherapy , immunotherapy , investigational agent within 4 week prior first dose ARQ 197 Known symptomatic brain metastasis Pregnant breastfeeding Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>